Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Gastrodia and Improved Hospital Discharge

Doses used in studies

mg/day: 1,200 (median 1,200, IQR 1,200–1,200) — 1 study

Time to effect

Median: 7 days · IQR 7 days–7 days · Range 7 days–7 days — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Adverse events occurred in 9.1% (7/77) of patients administered gastrodin and 14.1% (11/78) of patients administered the placebo, with none being drug-related.
from: Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac su

1 of 1 paper

Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac surgery: a randomized placebo controlled clinical trial.
- 2025-03-11
- RCT
- Critical care (London, England) 29(1)
- - Yun-Xiao Bai
  - Hui-Liang Wu
  - Wan-Li Xie
  - Xia Li
  - Jing-Jing Han
  - Jie Liu
  - Shi-Qiang Chen
  - Ping Yin
  - Nian-Guo Dong
  - Qing-Ping Wu
- PubMed: 40069830
- DOI: 10.1186/s13054-025-05331-9
3 Insights on
- Improved Hospital Discharge
- High evidence
- Clinical
The odds of hospital discharge were significantly greater in the gastrodin group (subhazard ratio, 1.20; 95% CI 1.00-1.84; p=0.049).
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
600 mg twice daily